Antibodies to human vascular endothelial growth factor 2

Details Antibodies to human vascular endothelial growth factor 2 Antibodies to human vascular endothelial growth factor 2

2006-09-19

2006-09-19

Landsman, Robert S. (Department: 1647)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C530S387100, C530S387300, C530S388150

Reexamination Certificate

active

07109308

ABSTRACT:
Disclosed is a human VEGF2 polypeptide and DNA(RNA) encoding such VEGF2 polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques and antibodies and antagonist against such polypeptide. Also disclosed is a method of using such polypeptide for stimulating wound healing and for vascular tissue repair. Also provided are methods of using the antagonists to inhibit tumor growth, inflammation and to treat diabetic retinopathy, rheumatoid arthritis and psoriasis. Diagnostic methods for detecting mutations in the VEGF2 coding sequence and alterations in the concentration of VEGF2 protein in a sample derived from a host are also disclosed.

REFERENCES:
patent: 5073492 (1991-12-01), Chen et al.
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5219739 (1993-06-01), Tischer et al.
patent: 5234908 (1993-08-01), Szabo et al.
patent: 5240848 (1993-08-01), Keck et al.
patent: 5283354 (1994-02-01), Lemischka
patent: 5326695 (1994-07-01), Andersson et al.
patent: 5607918 (1997-03-01), Eriksson et al.
patent: 5633147 (1997-05-01), Meissner et al.
patent: 5652225 (1997-07-01), Isner
patent: 5661133 (1997-08-01), Leiden and Barr
patent: 5693622 (1997-12-01), Wolff et al.
patent: 5776755 (1998-07-01), Alitalo et al.
patent: 5792453 (1998-08-01), Hammond et al.
patent: 5840693 (1998-11-01), Eriksson et al.
patent: 5861301 (1999-01-01), Terman et al.
patent: 5932540 (1999-08-01), Hu et al.
patent: 5935820 (1999-08-01), Hu et al.
patent: 6040157 (2000-03-01), Hu et al.
patent: 6121246 (2000-09-01), Isner
patent: 6130071 (2000-10-01), Alitalo et al.
patent: 6221839 (2001-04-01), Alitalo et al.
patent: 6245530 (2001-06-01), Alitalo et al.
patent: 6361946 (2002-03-01), Alitalo and Joukov
patent: 6403088 (2002-06-01), Alitalo et al.
patent: 6451764 (2002-09-01), Lee and Wood
patent: 6645933 (2003-11-01), Alitalo et al.
patent: 2006/0014252 (2006-01-01), Lyman
patent: 710696 (1999-09-01), None
patent: 0 186 084 (1986-07-01), None
patent: 0 399 816 (1990-11-01), None
patent: 0476983 (1992-03-01), None
patent: 0 506477 (1992-09-01), None
patent: 64-38100 (1989-02-01), None
patent: 2-117698 (1990-05-01), None
patent: WO-91/02058 (1991-02-01), None
patent: WO-92/14748 (1992-09-01), None
patent: WO 94/11506 (1994-05-01), None
patent: WO-95/19985 (1995-07-01), None
patent: WO-95/24414 (1995-09-01), None
patent: WO-95/24473 (1995-09-01), None
patent: WO-96/05856 (1996-02-01), None
patent: WO-96/39515 (1996-12-01), None
patent: WO-97/00271 (1997-01-01), None
patent: WO-97/05250 (1997-02-01), None
patent: WO-97/08320 (1997-03-01), None
patent: WO-97/09427 (1997-03-01), None
patent: WO-97/17442 (1997-05-01), None
patent: WO97/19694 (1997-06-01), None
patent: WO-98/06844 (1998-02-01), None
patent: WO-98-07832 (1998-02-01), None
patent: WO-98/24811 (1998-06-01), None
patent: WO-98/33917 (1998-06-01), None
patent: WO-98/39035 (1998-09-01), None
patent: WO-98/49300 (1998-11-01), None
patent: WO-98/55619 (1998-12-01), None
patent: WO-98/56936 (1998-12-01), None
patent: WO-99/02545 (1999-01-01), None
patent: WO-99/08522 (1999-02-01), None
patent: WO-99/20749 (1999-04-01), None
patent: WO-99/21590 (1999-05-01), None
patent: WO-99/46364 (1999-09-01), None
patent: WO 00/45835 (2000-08-01), None
patent: WO-00/73430 (2000-12-01), None
patent: WO-00/75163 (2000-12-01), None
patent: WO-01/57226 (2001-08-01), None
patent: WO-01/58956 (2001-08-01), None
patent: WO 02/11769 (2002-02-01), None
patent: WO 02/083704 (2002-10-01), None
patent: WO 02/083849 (2002-10-01), None
patent: WO 02/083850 (2002-10-01), None
patent: WO 03/097660 (2003-11-01), None
patent: 9-403464 (1996-01-01), None
Houck KA, et al. Mol. Endocrinol. 5(12):1806-1814, 1991.
Colwell DE, et al. Methods Enzymol. 121:42-51, 1986.
Achen et al., “Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor-2 (Flk1) and VEGF receptor 3 (Flt4),” Proc. Natl. Acad. Sci. (USA), 95(2): 548-553 (1998).
Andersson et al., “Assignment of interchain disulfide bonds in platelet-derived growth factor (PDGF) and evidence for agonist activity of monomeric PDGF,” J. Biol. Chem., 267(16): 11260-11266 (1992).
Alderson, R. F., Yourey, P. A., and Su, J. Y. (1999) Vascular endothelial cell growth factor (VEGF)-2 enhances the development of rat photoreceptor cells in vitro. Keystone Symposia, Ocular Cell and Molecular Biology, 202. (Abstract provided).
Andersson W.F., “Human gene therapy,”Science, 256:808-813 (1992).
Aprelikova et al., “FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter,” Cancer Research, 52:746-748 (1992).
Dignam et al., “Balbiani ring 3 inchironomus tentansencodes a 185-kDa secretory protein which is synthesized throughout the fourth larval instar,”Gene88:133-140 (1990).
Ferrara et al., “Molecular and biological properties of the vascular endothelial growth factor family of proteins,”Endocrine Rev.13(1): 18-32 (1992).
Finnerty et al., “Molecular cloning of murine FLT and FLT4,”Oncogene8(11): 2293-2298 (1993).
Heldin et al., “Structure of platelet-derived growth factor: implications for functional properties,”Growth Factors8:245-252 (1993).
Eichmann et al., “Avian VEGF-C: cloning, embryonic expression pattern and stimulation of the differentiation of VEGFR2-expressing endothelial cell precursors,”Development125(4): 743-752 (1998).
Pajusola et al., “FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines,”Cancer Research52:5738-5743 (1992).
Leung et al., “Vascular endothelial growth factor is a secreted angiogenic mitogen,”Science246:1306-1309 (1989).
Breier et al., “Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation,”Development114:521-532 (1992).
Bell et al., “Human epidermal growth factor precuror: cDNA sequence, expressionin vitroand gene organization,”Nucl. Acids Res.14(21): 8427-8446 (1986).
Berse et al., Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors,Mol. Biol. Cell.3:211-220 (1992).
Betsholtz et al., “cDNA sequence and chromosomal localization of human platelet-derived growth factor A-chain and its expression in tumor cell lines,”Nature320:695-699 (1986).
Claffey et al., “Vascular endothelial growth factor,”J. Biol. Chem.267(23): 16317-16322 (1992).
Corson et al., “Fibrillin binds calcium and is coded by cDNAs that reveal a multidomain structure and alternatively spliced exons at the 5′ end,”Genomics17:476-484 (1993).
Ferrara et al., “The vascular endothelial growth factor family of polypeptides,”J. Cellular Biochemistry47:211-218 (1991).
George et al., “Current Methods in Sequence Comparison and Analysis,” Macromolecular Seq. and Syn. Selected Meth—Application (Alan R. Liss), pp. 127-149 (1988).
Hu et al., “A novel regulatory function of proteolytically cleaved VEGF-2 for vascular endothelial smooth muscle cells,”FASEB J., 11:498-504 (1997).
Joukov et al., “A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases,”EMBO J.15(2): 290-298 (1996).
Joukov et al., “Proteolytic processing regulates receptor specificity and activity of VEGF-C,”EMBO J.16(13): 3898-3911 (1997).
Kaipainen et al., “The related FLT4, FLT1 and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells,”J. Exp. Med.178:2077-2088 (1993).
Keck et al., “Vascular permeability factor, an endothelial cell mitogen related to PDGF,”Science246: 1309 (1989).
Kingsley, D., “The TGF-β superfamily: new members, new receptors, and new genetic tests of function in different organisms,”Genes&Development8: 133-146 (1994)

Affiliated with

Also associated with

Rating

Antibodies to human vascular endothelial growth factor 2 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies to human vascular endothelial growth factor 2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to human vascular endothelial growth factor 2 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3540859